Edition:
United States

Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

3.52USD
4:00pm EDT
Change (% chg)

$0.05 (+1.44%)
Prev Close
$3.47
Open
$3.49
Day's High
$3.53
Day's Low
$3.40
Volume
7,928
Avg. Vol
33,508
52-wk High
$4.30
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

Compugen Announces Exclusive License Agreement With Medimmune
Monday, 2 Apr 2018 08:43am EDT 

April 2 (Reuters) - Compugen Ltd ::SPECIFIC ANTIBODY PRODUCTS‍​.SEC FILING.CO ALSO ELIGIBLE TO RECEIVE UP TO $200 MILLION IN DEVELOPMENT, REGULATORY, COMMERCIAL MILESTONES ON FUTURE PRODUCT SALES.  Full Article

Compugen Reports Q4 Loss Per Share Of $0.18
Wednesday, 21 Feb 2018 07:07am EST 

Feb 21 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS.Q4 LOSS PER SHARE $0.18.COMPUGEN - AS OF DEC 31, 2017, CASH, CASH RELATED ACCOUNTS, SHORT-TERM AND LONG-TERM BANK DEPOSITS TOTALED $30.4 MILLION, COMPARED WITH $61.5 MILLION LAST YEAR.  Full Article

COMPUGEN REPORTS Q3 LOSS PER SHARE $0.19
Tuesday, 7 Nov 2017 07:11am EST 

Nov 7 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS THIRD QUARTER 2017 RESULTS.Q3 LOSS PER SHARE $0.19.‍AS OF SEPTEMBER 30, 2017, CASH AND CASH RELATED ACCOUNTS TOTALED $38.5 MILLION, COMPARED WITH $61.5 MILLION AS OF DECEMBER 31, 2016​.  Full Article

Compugen to initiate manufacturing of COM902
Monday, 6 Nov 2017 07:00am EST 

Nov 6 (Reuters) - Compugen Ltd :Compugen Ltd - ‍advancing COM902 into manufacturing in anticipation of filing an investigational new drug (IND) application in 2019​.Compugen Ltd - ‍entered into process development and manufacturing service agreement with Bayer Healthcare LLC (Bayer) to produce COM902.Compugen Ltd - ‍working towards filing IND for COM902 in 2019​.  Full Article

Compugen appoints Paul Sekhri as new board chairman
Wednesday, 2 Aug 2017 07:22am EDT 

Aug 2 (Reuters) - Compugen Ltd :Compugen welcomes paul sekhri as its new chairman of the board.Compugen ltd - sekhri will succeed martin gerstel, who announced his intention to retire from this role in february of this year.  Full Article

Compugen Q2 loss per share $0.18
Wednesday, 2 Aug 2017 07:20am EDT 

Aug 2 (Reuters) - Compugen Ltd :Compugen reports second quarter 2017 results.Q2 loss per share $0.18.Compugen ltd - ‍names paul sekhri as chairman of board effective october 2, 2017​.Compugen ltd - ‍as of june 30, 2017, cash and cash related accounts totaled $46.1 million, compared with $61.5 million as of december 31, 2016​.Compugen ltd - ‍now planning on filing an investigational new drug application for com701 towards end of q1 of 2018​.  Full Article

Compugen discloses updates to collaborative activities with Bayer in immuno-oncology
Wednesday, 26 Jul 2017 07:09am EDT 

July 26 (Reuters) - Compugen Ltd ::Compugen discloses updates to collaborative activities with bayer in immuno-oncology.Compugen - agreement with Bayer AG involves research, development, commercialization of antibody-based therapeutics against cgen-15001t and cgen-15022.Compugen Ltd - it has been determined current collaboration will focus solely on cgen-15001t, all rights to cgen-15022 will be returned to Compugen.  Full Article